ELI LILLY & Co (LLY) operating KPIs
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1417.54+43.84 (+3.19%)
Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%
Eli Lilly cEO annual total compensation ($) ($)
DEF 14A Proxy Statements (CEO Pay Ratio Disclosure)
Latest, FY2025
36,698,337
Period ended Dec 31, 2025
Change on a year earlier
+25.5%
29,242,926 in FY2024
History
7 years
Since FY2019
Sources
7
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | CEO annual total compensation ($) ($) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 36,698,337 | +25.5% | Proxy Statement (DEF 14A FY2026) (filed 2026-03-20) ↗ |
| FY2024 | Dec 31, 2024 | 29,242,926 | +10.1% | Proxy Statement (DEF 14A FY2025) (filed 2025-03-21) ↗ |
| FY2023 | Dec 31, 2023 | 26,565,732 | +24.1% | Proxy Statement (DEF 14A FY2024) (filed 2024-03-22) ↗ |
| FY2022 | Dec 31, 2022 | 21,398,135 | -0.5% | Proxy Statement (DEF 14A FY2023) (filed 2023-03-17) ↗ |
| FY2021 | Dec 31, 2021 | 21,509,985 | -9.3% | Proxy Statement (DEF 14A FY2022) (filed 2022-03-18) ↗ |
| FY2020 | Dec 31, 2020 | 23,708,629 | +11.4% | Proxy Statement (DEF 14A FY2021) (filed 2021-03-19) ↗ |
| FY2019 | Dec 31, 2019 | 21,283,242 | – | Proxy Statement (DEF 14A FY2020) (filed 2020-03-20) ↗ |
Cite this data
StockData. (2026). Eli Lilly CEO annual total compensation ($) ($), annual FY2019–FY2025 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/comp_ceo_total
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.